# Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

> **NCT05338580** · PHASE2 · WITHDRAWN · sponsor: **TJ Biopharma Co., Ltd.**

## Conditions studied

- First-line Non-small-cell Lung Cancer
- First-line Urothelial Carcinoma
- Second-line Urothelial Carcinoma
- Second-line Melanoma

## Interventions

- **DRUG:** TJ271 Injection in Combination with Pembrolizumab

## Key facts

- **NCT ID:** NCT05338580
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-31
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company Development strategy adjustment
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338580, "Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05338580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*